Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 4/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.41 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TYMS | P04818 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13907108 | 0.83 | BACE1 (0.50) | BACE1ACHEMPOPABPC1HRH4 | |
| SCHEMBL8141994 | 0.79 | CHEK1 (0.41) | BACE1ACHECHEK1MPOHRH4 | |
| SCHEMBL20880351 | 0.79 | BACE1 (0.44) | BACE1ACHEHRH4 | |
| SCHEMBL832149 | 0.78 | BACE1 (0.58) | BACE1ACHEHTTTYMSRAB9A | |
| SCHEMBL13906869 | 0.76 | BACE1 (0.41) | BACE1ACHEMPOHRH4HTT | |
| SCHEMBL17646468 | 0.75 | BACE1 (0.59) | BACE1ACHEF2 | |
| SCHEMBL11346168 | 0.75 | BACE1 (0.53) | BACE1ACHEMPOPABPC1HRH4 | |
| SCHEMBL4257660 | 0.73 | BACE1 (0.47) | BACE1ACHE | |
| SCHEMBL22233563 | 0.73 | KMT2A (0.45) | BACE1KMT2AMAPT | |
| SCHEMBL21556304 | 0.73 | F2 (0.39) | CHEK1MPOHTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3567035-A1 | N-SUBSTITUTED 2,5-DIOXO-AZOLINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Canbas Co. Ltd. (JP) | 2019-11-13 | — | — | EP | disclosed |
| EP-3088397-A1 | COMPOUNDS THAT ABROGATE THE CELL CYCLE G2 CHECKPOINT FOR USE IN THE TREATMENT OF CANCER | Canbas Co. Ltd. (JP) | 2016-11-02 | — | — | EP | disclosed |